Video

Dr. Olawaiye on Front Line Treatment Sequencing Considerations in Ovarian Cancer

Alexander B. Olawaiye, MD, discusses front line treatment sequencing considerations in ovarian cancer.

Alexander B. Olawaiye, MD, director, Gynecologic Oncology Research Program, professor, Gynecologic Oncology, Department of Obstetrics, Gynecology & Reproductive Sciences, Magee-Women’s Hospital, the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, discusses front line treatment sequencing considerations in ovarian cancer.

The ovarian cancer treatment landscape currently faces the unique problem of having several agents available for treatment in the frontline setting, Olawaiye says. Due to the various treatment choices, it is crucial for clinicians to monitor the latest data when deciding between certain treatments, Olawaiye explains.

Patient costs, including those beyond monetary expenses, need to be factored into treatment decisions for this patient population, Olawaiye continues. Using the data and examining potential toxicities are important steps toward identifying the proper treatment for each patient, Olawiaye concludes.

Related Videos
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Kathleen N. Moore, MD, MS
Paolo Caimi, MD
Dr Oveisi on the Importance of Patient Counseling Prior to CAR T-Cell Therapy in Myeloma